MATTHEW WANAT to Factor Xa Inhibitors
This is a "connection" page, showing publications MATTHEW WANAT has written about Factor Xa Inhibitors.
Connection Strength
0.339
-
Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan; 25(1):63-70.
Score: 0.224
-
Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity. Clin Appl Thromb Hemost. 2015 Sep; 21(6):513-20.
Score: 0.115